

# Frank H J Van Den Hoogen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7680967/publications.pdf>

Version: 2024-02-01

107  
papers

10,728  
citations

109137

35  
h-index

33814

99  
g-index

109  
all docs

109  
docs citations

109  
times ranked

10524  
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.5	1,705
3	The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. <i>Arthritis and Rheumatism</i> , 2000, 43, 155-163.	6.7	1,250
4	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
5	The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 1831-1835.	6.7	573
6	Mortality in systemic sclerosis: An international meta-analysis of individual patient data. <i>American Journal of Medicine</i> , 2005, 118, 2-10.	0.6	419
7	Recombinant human anti- $\alpha$ transforming growth factor $\beta$ 1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. <i>Arthritis and Rheumatism</i> , 2007, 56, 323-333.	6.7	415
8	Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. <i>Arthritis Research</i> , 2002, 4, 87.	2.0	303
9	Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab. <i>Arthritis and Rheumatology</i> , 2018, 70, 60-68.	2.9	142
10	Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1503-1507.	0.5	136
11	Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. <i>BMJ</i> , The, 2015, 350, h1389-h1389.	3.0	135
12	Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2009, 36, 2164-2170.	1.0	120
13	High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: Results of an open study to assess feasibility, safety, and efficacy. <i>Arthritis and Rheumatism</i> , 2001, 44, 754-760.	6.7	110
14	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. <i>Arthritis and Rheumatism</i> , 2008, 59, 699-705.	6.7	109
15	Unraveling SSc Pathophysiology; The Myofibroblast. <i>Frontiers in Immunology</i> , 2018, 9, 2452.	2.2	103
16	Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar $\alpha$ SB $\beta$ 4. <i>Arthritis and Rheumatology</i> , 2018, 70, 1408-1418.	2.9	90
17	Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1849-1854.	0.5	88
18	Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 775-782.	6.7	86

#	ARTICLE	IF	CITATIONS
19	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. <i>BioDrugs</i> , 2018, 32, 397-404.	2.2	82
20	Validation of potential classification criteria for systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 358-367.	1.5	77
21	Improved insulin sensitivity by anti-TNF $\alpha$ antibody treatment in patients with rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 558-559.	0.5	70
22	Circulating Leptin and Adiponectin Concentrations During Tumor Necrosis Factor Blockade in Patients with Active Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 724-730.	1.0	68
23	Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis and Rheumatology</i> , 2017, 69, 301-308.	2.9	56
24	Identity of the RNase MRP- and RNase P-associated Th/To autoantigen. <i>Arthritis and Rheumatism</i> , 2002, 46, 3266-3272.	6.7	54
25	Disease-related and psychosocial factors associated with depressive symptoms in patients with systemic sclerosis, including fear of progression and appearance self-esteem. <i>Journal of Psychosomatic Research</i> , 2012, 72, 199-204.	1.2	54
26	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	0.9	53
27	Total ankle prostheses in rheumatoid arthropathy. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2009, 80, 440-444.	1.2	52
28	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	2.4	52
29	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2017, 56, 1302-1311.	0.9	51
30	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012, 64, 351-357.	1.5	49
31	Treatment of the inflammatory myopathies: update and practical recommendations. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1183-1190.	0.9	47
32	Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis: a randomised, double-blinded, sham-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, annrheumdis-2018-214104.	0.5	43
33	Nontuberculous mycobacterial bursitis and arthritis of the shoulder. <i>Skeletal Radiology</i> , 1998, 27, 33-35.	1.2	42
34	Fatigue in knee and hip osteoarthritis: the role of pain and physical function. <i>Rheumatology</i> , 2011, 50, 1894-1900.	0.9	41
35	Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 299.	0.8	39
36	Milk-Derived Nanoparticle Fraction Promotes the Formation of Small Osteoclasts But Reduces Bone Resorption. <i>Journal of Cellular Physiology</i> , 2017, 232, 225-233.	2.0	36

#	ARTICLE	IF	CITATIONS
37	Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 12.	0.8	35
38	Validity of the Fear of Progression Questionnaire—Short Form in patients with systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 930-934.	1.5	34
39	Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. <i>Rheumatology</i> , 2016, 55, 2001-2008.	0.9	34
40	Survivorship of the KUDO total elbow prosthesis— comparative study of cemented and uncemented ulnar components: 89 cases followed for an average of 6 years. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2007, 78, 258-262.	1.2	32
41	The effects of doxycycline on reducing symptoms in knee osteoarthritis: results from a triple-blinded randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1191-1196.	0.5	32
42	The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 939-945.	1.1	32
43	Eosinophilic fasciitis in a child mimicking a myopathy. <i>Neuromuscular Disorders</i> , 2006, 16, 144-148.	0.3	30
44	Shoulder hemiarthroplasty in rheumatoid arthritis 19 cases reexamined after 1-17 years. <i>Acta Orthopaedica</i> , 1997, 68, 243-245.	1.4	29
45	Poor psychological health status among patients with inflammatory rheumatic diseases and osteoarthritis in multidisciplinary rehabilitation: Need for a routine psychological assessment. <i>Disability and Rehabilitation</i> , 2010, 32, 836-844.	0.9	28
46	Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. <i>RMD Open</i> , 2018, 4, e000654.	1.8	28
47	Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1334-1338.	0.5	26
48	Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 184.	0.8	25
49	Suppression of the inflammatory response by disease-inducible interleukin-10 gene therapy in a three-dimensional micromass model of the human synovial membrane. <i>Arthritis Research and Therapy</i> , 2016, 18, 186.	1.6	21
50	Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity. <i>Frontiers in Immunology</i> , 2018, 9, 2388.	2.2	21
51	Interventions to support shared decision making for medication therapy in long term conditions: A systematic review. <i>Patient Education and Counseling</i> , 2020, 103, 254-265.	1.0	21
52	A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. <i>Rheumatology</i> , 2017, 56, 973-980.	0.9	20
53	High-Dose Intravenous Pulse Methotrexate in Patients With Eosinophilic Fasciitis. <i>JAMA Dermatology</i> , 2016, 152, 1262.	2.0	19
54	Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 349-358.	0.8	19

#	ARTICLE	IF	CITATIONS
55	Costa Utility and Cost Effectiveness Analyses of Face-to-Face Versus Telephone-Based Nonpharmacologic Multidisciplinary Treatments for Patients With Generalized Osteoarthritis. <i>Arthritis Care and Research</i> , 2016, 68, 502-510.	1.5	18
56	Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 403.	0.7	18
57	Development and content of a group-based intervention to improve medication adherence in non-adherent patients with rheumatoid arthritis. <i>Patient Education and Counseling</i> , 2012, 89, 143-151.	1.0	17
58	Short fatigue questionnaire: Screening for severe fatigue.. <i>Journal of Psychosomatic Research</i> , 2020, 137, 110229.	1.2	17
59	Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2260-2261.	0.5	15
60	Cross-Language Measurement Equivalence of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis: A Comparison of Canadian and Dutch Patients. <i>PLoS ONE</i> , 2013, 8, e53923.	1.1	14
61	Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial. <i>Trials</i> , 2018, 19, 449.	0.7	14
62	Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. <i>Rheumatology</i> , 2022, 61, 2307-2315.	0.9	14
63	Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor $\alpha$ -neutralising treatments in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1525-1530.	0.5	13
64	Systemic sclerosis: To subset or not to subset, that is the question. <i>European Journal of Rheumatology</i> , 2020, 7, 222-227.	1.3	13
65	Treatment Beliefs Underlying Intended Treatment Choices in Knee and Hip Osteoarthritis. <i>International Journal of Behavioral Medicine</i> , 2018, 25, 198-206.	0.8	12
66	Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1655-1659.	0.5	10
67	Patient Acceptable Symptom State in Knee Osteoarthritis Patients Succeeds Across Different Patient-reported Outcome Measures Assessing Physical Function, But Fails Across Other Dimensions and Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2018, 45, 122-127.	1.0	10
68	Most Important Frequently Asked Questions From Patients With Hip or Knee Osteoarthritis: A Best Worst Scaling Exercise. <i>Arthritis Care and Research</i> , 2019, 71, 885-892.	1.5	10
69	The -2518A>G promoter polymorphism in the CCL2 gene is not associated with systemic sclerosis susceptibility or phenotype: Results from a multicenter study of European Caucasian patients. <i>Human Immunology</i> , 2009, 70, 130-133.	1.2	9
70	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). <i>Journal of Rheumatology</i> , 2010, 37, 1673-1679.	1.0	9
71	An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation. <i>Rheumatology</i> , 2016, 55, 2023-2032.	0.9	9
72	Preparing for an orthopedic consultation using an eHealth tool: a randomized controlled trial in patients with hip and knee osteoarthritis. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 92.	1.5	9

#	ARTICLE	IF	CITATIONS
73	Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 1550-1555.	0.9	8
74	Comparison of physical activity among different subsets of patients with knee or hip osteoarthritis and the general population. <i>Rheumatology International</i> , 2020, 40, 383-392.	1.5	8
75	Social Support, Disease-Related Cognitions and Coping as Predictors of Depressed Mood in Systemic Sclerosis. <i>Cognitive Therapy and Research</i> , 2008, 32, 434-447.	1.2	7
76	Effect of naproxen on the hypothalamic-pituitary-adrenal axis in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 22-28.	1.1	6
77	What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?. <i>RMD Open</i> , 2017, 3, e000327.	1.8	6
78	What moves the rheumatologist? Unravelling decision making in the referral of systemic sclerosis patients to health professionals: a qualitative study. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky027.	0.3	6
79	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.201594.	1.0	6
80	Systemic Sclerosis: New Insights in Autoimmunity. <i>Proceedings of the Society for Experimental Biology and Medicine</i> , 1999, 222, 1-8.	2.0	6
81	An Electronic Health Tool to Prepare for the First Orthopedic Consultation: Use and Usability Study. <i>JMIR Formative Research</i> , 2019, 3, e13577.	0.7	6
82	Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritis. <i>Rheumatology</i> , 2010, 49, 588-591.	0.9	5
83	Cognitive-Behavioural Therapy Targeting Fear of Progression in an Interdisciplinary Care Program: A Case Study in Systemic Sclerosis. <i>Journal of Clinical Psychology in Medical Settings</i> , 2014, 21, 297-312.	0.8	4
84	Use and usability of the dr. Bart app and its relation with health care utilisation and clinical outcomes in people with knee and/or hip osteoarthritis. <i>BMC Health Services Research</i> , 2021, 21, 444.	0.9	4
85	Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 32-37.	0.4	4
86	The mutations in the fibronectin gene described in japanese patients with systemic sclerosis are not present in dutch patients. <i>Arthritis and Rheumatism</i> , 1991, 34, 490-492.	6.7	3
87	Isolation and Characterization of Single Anti-U1A-specific B Cells from Autoimmune Patients. <i>Annals of the New York Academy of Sciences</i> , 1997, 815, 440-442.	1.8	3
88	InforMatrix®: treatment of rheumatoid arthritis using biologicals. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1769-1789.	0.9	3
89	Specificity of Systemic Sclerosis Classification Criteria. <i>Journal of Rheumatology</i> , 2015, 42, 2512-2512.	1.0	3
90	Economic evaluation of the dr. Bart app in people with knee and/or hip osteoarthritis. <i>Arthritis Care and Research</i> , 2021, , .	1.5	3

#	ARTICLE	IF	CITATIONS
91	Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER): Protocol for a Longitudinal Observational Study. <i>JMIR Research Protocols</i> , 2021, 10, e31647.	0.5	3
92	What does the clinician need to improve patient care in systemic sclerosis?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1129-1131.	0.5	2
93	Evolving Concepts of Diagnosis and Classification. , 2012, , 53-69.		2
94	Evolving Concepts of Diagnosis and Classification. , 2017, , 49-64.		2
95	Three-year trajectories of disability and fatigue in systemic sclerosis: a cohort study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 48-55.	0.4	2
96	Anti-cyclic citrullinated peptide antibody in early rheumatoid arthritis: Comment on the editorial by Scott. <i>Arthritis and Rheumatism</i> , 2003, 48, 857-857.	6.7	1
97	Response to: "Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis"™ by Wu<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e25-e25.	0.5	1
98	(Bi)Weekly folic acid supplementation might be inferior to a daily folic acid dosing schedule in the prevention of methotrexate-related toxicity in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 767-8.	0.4	1
99	Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 140-143.	0.4	1
100	Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 367-372.	0.4	1
101	Analysis of anti"U1 RNA antibodies in patients with connective tissue diseases: Comment on the article by Hoffman et al. <i>Arthritis and Rheumatism</i> , 1996, 39, 1265-1266.	6.7	0
102	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2019, , .	0.9	0
103	SAT0259"€...PREDICTIVE FACTORS FOR TREATMENT RELATED MORTALITY AND MAJOR ADVERSE EVENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS: RESULTS OF A LONG TERM FOLLOW-UP MULTI-CENTRE STUDY. , 2019, , .		0
104	SAT0282"€...EFFICACY AND SAFETY OF ORAL PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG IN PATIENTS WITH SYSTEMIC SCLEROSIS -ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IN DAILY CLINICAL PRACTICE, A CASE SERIES. , 2019, , .		0
105	OP0079"€...HPR NON-PHARMACOLOGICAL CARE IN SYSTEMIC SCLEROSIS: OPENING THE BLACK BOX. , 2019, , .		0
106	Response to: 'Is it time to redefine the role of low-dose radiotherapy for benign disease?' by Montero <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e35-e35.	0.5	0
107	Short-term clinical worsening is a clear predictor for worsening at 2 years in established knee and hip osteoarthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 414-421.	0.4	0